IMPORTANCE Maternal obesity, pregestational type 1 and 2 diabetes, and gestational diabetes have been reported to increase the risk of autism spectrum disorder and attention-deficit/hyperactivity disorder in the mothers' offspring. However, the associations of maternal diabetes disorders and body mass index jointly with psychiatric disorders among offspring are less well documented, especially for type 2 diabetes.
Data on purchase of psychotropic drugs for offspring were extracted from the Finnish Register on Reimbursement Drugs and applied as outcome variables in a second model. The following ATC codes were used: N05 (antipsychotics, anxiolytics, hypnotics, and sedatives), N06A (antidepressants), and N06B (psychostimulants and nootropics). Also, data on mothers' previous inpatient care associated with pregestational mental health disorders (International Classification of Diseases, Eighth Revision codes 290-317 in 1969-1986, International Classification of Diseases, Ninth Revision codes 290-319 in 1987-1995, and ICD-10 codes F00-F99 in 1996-2014 from HILMO) and purchase of ATC group N05 or N06 medications during pregnancy were used as covariates.
Information on offspring birth year, sex, any perinatal problem (birth weight <2500 g or gestational age <37 weeks, or small birth weight according to gestational age according to Finnish sex-specific standards 23, 24 ), number of fetuses, mode of delivery, maternal age at delivery, parity, maternal marital status, mother's country of birth, and maternal smoking were obtained from the Drugs and Pregnancy database. Information on mothers' diagnoses of systemic inflammatory disorders (ICD-10 codes M30-M36 in 2004-2014) as primary or secondary diagnoses was obtained from HILMO. The ICD-10 was in routine use over the period between 1996 and 2014. Maternal and birth characteristics of the cohort studied are shown in eTable 1 in the Supplement.
Statistical Analysis
Cox proportional hazards modeling was used to estimate the association of exposure to maternal prepregnancy obesity and different types of diabetes, the latter stratified by BMI categories, with the outcomes offspring psychiatric diagnosis and purchase of psychotropic drug (sensitivity analysis).
For maternal BMI, the strata overweight, moderately obese, and severely obese were compared with normal weight. Covariates were adjusted for as indicated in Figure 1, Figure 2 , Table 2, and Table 3 .
Hazard ratios (HRs) with 95% CIs were reported as measures of effect size. Two-sided P < .05 was considered statistically significant. All statistical analyses were performed using SAS statistical software version 9.3 (SAS Institute).
In a sensitivity analysis, the first 2 subsequent singleton pregnancies of the same mother during the study period were included (247 681 pregnancies). The first child born during the study period was not necessarily the first child born to the mother. The exposures for maternal diabetes (eTable 2 in the Supplement) and BMI (eTable 3 in the Supplement) for the 2 offspring were recorded. Because only a few sibling pairs were discordant for a maternal diabetes category, exposure-discordant sibling pair analysis could not be performed. Instead, the risk for the outcome in the second offspring given maternal diabetes exposure was estimated irrespectively of the older sibling (model 1). In an attempt to adjust for familial risk of the outcome, the outcome for the older sibling was also followed up for psychiatric For 647 099 births, graphs show adjusted hazard ratios (HRs) with error bars representing 95% CIs for offspring receiving any psychotropic medication (A); anxiolytics, hypnotics, and sedatives (B); antidepressants (C); and stimulants (D). The analyses were adjusted for offspring birth year, sex, perinatal problems, number of fetuses, cesarean delivery, maternal age group at delivery, parity, mother's marital status at birth, mother's country of birth, maternal smoking, maternal psychiatric disorder, maternal use of psychotropic medication during pregnancy (Anatomic Therapeutic Chemical groups N05 and N06), and maternal systemic inflammatory disease. Body mass index (calculated as the weight in kilograms divided by height in meters squared) was categorized as severely obese (Ն35), obese (Ն30 to <35), overweight (Ն25 to <30), and normal (Ն18.5 to <25). Data are shown for 647 099 births. For ICD-10 codes F51 (sleeping disorders), F80 to F83 (specific developmental disorders), and F98 (other behavioral and emotional disorders), the birth cohorts for 2004 to 2014 were used; for ICD-10 codes F50 (eating disorders) and F84 (ASD), the birth cohorts for 2004 to 2013 were used; and for ICD-10 codes F30 to F39 and F92 (mood disorders), F40 to F43 and F93 (anxiety disorders), F60 to F69 (personality disorders), F70 to F79 (intellectual disabilities), and F90 to F91 (ADHD and conduct disorders), the birth cohorts for 2004 to 2012 were used. All were followed up until 2014. Type 2 diabetes was defined as pregestational type 2 diabetes (ICD-10 code E11, E14, or O24.1 and/or the use of Anatomic Therapeutic Chemical class A10B drugs) without insulin purchase before or during pregnancy. Gestational diabetes was defined as an ICD-10 code O24.4 diagnoses without purchase of insulin before or during pregnancy. Insulintreated pregestational diabetes was defined as pregestational diabetes with the purchase of insulin before pregnancy.
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The analyses were adjusted for offspring birth year, sex, perinatal problems, number of fetuses, cesarean delivery, maternal age group at delivery, parity, mother's marital status at birth, mother's country of birth, maternal smoking, maternal psychiatric disorder, maternal use of psychotropic medication during pregnancy (Anatomic Therapeutic Chemical class N05 or N06 drugs), and maternal systemic inflammatory disease. The reference is births to normal-weight mothers without diabetes and without purchase of insulin. Maternal BMI was categorized as severely obese (Ն35), obese (Ն30 to <35), overweight (Ն25 to <30), and normal (18.5 to <25).
Results
The mean (SD) age of mothers was 30.20 ( antipsychotics, anxiolytics, hypnotics, and sedatives (ATC group N05); antidepressants (ATC group N06A); and stimulants (ATC group N06B). For ICD-10 codes F51 (sleeping disorders), F80 to F83 (specific developmental disorders), and F98 (other behavioral and emotional disorders), the birth cohorts 2004 to 2014 were used; for ICD-10 codes F50 (eating disorders) and F84 (autism spectrum disorder), the birth cohorts 2004 to 2013 were used; and for ICD-10 codes F30 to F39 and F92 (mood disorders), F40 to F43 and F93 (anxiety disorders), F60 to F69 (personality disorders), F70 to F79 (intellectual disabilities), and F90 to F91 (attention-deficit/hyperactivity disorder and conduct disorders), the birth cohorts 2004 to 2012 were used. All were followed up until 2014. Insulin-treated pregestational diabetes was defined as pregestational diabetes with purchase of insulin before pregnancy. Type 2 diabetes was defined as pregestational type 2 diabetes (ICD-10 code E11, E14, or O24.1 and/or ATC group A10B) without insulin purchase before or during pregnancy. Gestational diabetes was defined as an ICD-10 code O24.4 diagnoses without purchase of insulin before or during pregnancy. b The analyses were adjusted for offspring birth year, sex, perinatal problems, number of fetuses, cesarean delivery, maternal age group at delivery, parity, mother's marital status at birth, mother's country of birth, maternal smoking, maternal psychiatric disorder, maternal use of psychotropic medication during pregnancy (ATC group N05 or N06), and maternal systemic inflammatory disease. The reference is births to normal-weight mothers without diabetes and without purchase of insulin. Maternal BMI was categorized as severely obese (Ն35), obese (Ն30 to <35), overweight (Ն25 to <30), and normal (18.5 to <25). compared with mothers with BMI less than 25, where associations with the latter 2 diagnoses groups were reported from these birth cohorts previously 21 (Figure 1 and Table 2 ).
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Second, there were statistically significant interactions between maternal prepregnancy BMI and maternal diabetes with offspring having any ICD-10 F code diagnosis (insulin-treated pregestational diabetes, P for interaction < .001; type 2 diabetes, P for interaction < .001; gestational diabetes, P for interaction = .007). Therefore, the associations between maternal diabetes and offspring disorders were assessed after stratifying for maternal prepregnancy BMI. Maternal diabetes implied, on top of obesity, an additional increased risk for offspring to receive any ICD-10 F code diagnosis, with the pointwise effect size generally larger in the order insulin-treated pregestational diabetes first, then type 2 diabetes, and then gestational diabetes (Figure 1 (Table 2) . Previously, we reported that the offspring of severely obese mothers who had insulin-treated pregestational diabetes had a pointwise 6-time increased risk of ASD and ADHD, but the nondiabetic reference group included type 2 diabetes. 21 For type 2 diabetes, compared with the offspring of normal-weight mothers without diabetes. Moreover, these risks for mood disorders and ADHD or conduct disorders were higher than those for the offspring of severely obese mothers without diabetes (mood disorders, HR, 1.26; 95% CI, 0.91-1.74; ADHD or conduct disorders, HR, 1.87; 95% CI, 1.58-2.23). Exposure to gestational diabetes was not associated with any specific ICD-10 F code diagnosis. As for insulin-treated pregestational diabetes, data for gestational diabetes were not previously reported for mood, anxiety, or personality disorders or intellectual disabilities. 21 Thus, among mothers with severe obesity, the effect sizes were lower for type 2 diabetes than for insulin-treated pregestational diabetes in association with offspring mood disorders, specific developmental disorders, ASD, ADHD or conduct disorders, and other behavioral and emotional disorders. Compared with severely obese mothers with gestational diabetes, the effect sizes for severely obese mothers with type 2 diabetes were higher for mood disorders, specific developmental disorders, ASD, and ADHD or conduct disorders ( Figure 1 and Table 2 ).
Third, in a sensitivity analysis, we used the purchase of psychotropic medication, including ATC group N05 drugs (antipsychotics, anxiolytics, hypnotics, and sedatives), group N06A drugs (antidepressants), and group N06B drugs (stimulants and nootropics), as an estimate of offspring psychiatric disorders. The findings for offspring of mothers with type 2 diabetes are novel, but the results for the offspring of mothers with insulin-treated pregestational diabetes and gestational diabetes were reported previously 21 with a nondiabetic reference group including type 2 diabetes (Table 3 and Figure 2 ). Similar to the analysis results where psychiatric diagnoses were outcome variables, offspring of severely obese mothers with insulin-treated pregestational diabetes or type 2 diabetes had the highest effect size on psychotropic medication purchase. The effect size for any purchase among offspring to severely obese mothers with type 2 diabetes (HR, 2.25; 95% CI, 1.66-3.03) was higher than that for severely obese mothers without diabetes (HR, 1.68; 95% CI, 1.50-1.89) and was lower than that for offspring of severely obese mothers with insulin-treated pregestational diabetes (HR, 4.20; 95% CI, 2.67-6.59). However, antidepressants were markedly more common among the offspring of severely obese mothers with type 2 diabetes (HR, 6.85; 95% CI, 2.53-18.54) compared with the offspring of severely obese mothers without diabetes (HR, 0.85; 95% CI, 0.31-2.28) ( Figure 2C and Table 3 ). Of note, we could only exclude marked confounding from maternal inpatient psychiatric disorders and maternal purchase of ATC group N05 or N06 drugs (yes or no) during pregnancy, as seen for 1.8% and 5.8% of the mothers, respectively (eTable 1 in the Supplement).
Fourth, in a second sensitivity analysis, we analyzed all the first 2 siblings born to the mothers in an attempt to adjust for familiar risk of the outcome (247 681 mothers). Most of the sibling pairs were concordant for the maternal diabetes (>97%) and BMI group (>50%) exposure (eTable 2 and eTable 3 in the Supplement), which prohibited an exposure-discordance analysis. We estimated the risk of psychiatric disorder and psychotropic medication for the second offspring given their exposure to diabetes without (model 1) and with (model 2) adjustment for the corresponding psychiatric outcome in the older sibling irrespective of the older sibling's exposure. The effect sizes for the second sibling were similar to those in the whole cohort ( Table 2 and Table 3 ; eTable 4 in the Supplement), and there was no significant difference in effect sizes between model 1 and model 2 (ie, by adjusting for the older sibling's psychiatric outcome) (eTable 4 in the Supplement).
Discussion
In this nationwide cohort study in Finland, we found that maternal moderate and severe obesity combined with type 2 diabetes were associated with mood disorders, intellectual disabilities, specific developmental disorders, and ADHD or conduct disorders among their offspring. The association with mood disorders was unique to the joint associations of high BMI and type 2 diabetes, whereas for the other disorders, an association with high BMI alone was also found, albeit with a smaller effect size than the joint association. For mothers with severe obesity, the effect size of type 2 diabetes on their offspring having any ICD-10 F code diagnosis was between those of mothers with insulintreated pregestational diabetes and gestational diabetes. For the first time, to our knowledge, we also report that insulin-treated pregestational diabetes in severely obese mothers was associated with mood disorders and intellectual disability among their offspring, with large effect sizes (pointwise HRs of 8.03 and 3.64, respectively), whereas we reported previously that severely obese mothers who had insulin-treated pregestational diabetes had an estimated pointwise HR of 6 for ASD and ADHD or conduct disorders. 21 For normal-weight mothers, there were no associations of either type 2 diabetes or insulin-treated pregestational diabetes with offspring having an ICD-10 F code diagnosis. For mothers with severe obesity, gestational diabetes was associated with disorders in the offspring only when we considered any ICD-10 F code diagnosis. The fact that the joint association of severe obesity with diabetes was stronger than that of either alone might reflect a stronger neural exposure to inflammation, oxidative stress, lipotoxicity, hyperglycemia, and insulin resistance in the former setting. During pregnancy, insulin resistance is gradually increased to ensure adequate carbohydrate supply for the growing fetus, and along with this, postprandial glucose levels, basal and stimulated insulin secretion, and hepatic glucose production are elevated. An obese and/or diabetic state can aggravate these pregnancy-related metabolic changes. For example, low-grade inflammation, insulin resistance, and hyperinsulinemia are commonly seen in a nonpregnant severely obese setting. 8 The maternal insulin resistance and hyperglycemia further lead to increased placental cytokine release, glucose transfer, and fetal insulin secretion. 9, 25 Specifically, compared with normal-weight mothers without diabetes, the pointwise effect size for mood disorders was 2 to 3 times higher for obese mothers with type 2 diabetes and was 3 to 8 times higher for obese mothers with insulin-treated pregestational diabetes. We found an effect size greater than 3 for ADHD among offspring of severely obese mothers with type 2 diabetes compared with offspring of normal-weight mothers without diabetes, double that of offspring of moderately obese mothers with type 2 diabetes. However, offspring of normal-weight mothers with type 2 diabetes had no increased risk of ADHD. Accordingly, a Norwegian case-control study 26 of 2 322 657 mothers, most of whom were of normal weight, showed that maternal type 2 diabetes without considering BMI was not associated with offspring ADHD. Conversely, the offspring of mothers with severe obesity who had insulin-treated pregestational diabetes had an approximately 6-time increased risk of ADHD or conduct disorders. 21 The effect size for offspring of women with severe obesity who had type 2 diabetes to have ASD was 2 times higher than that for offspring of normalweight mothers without diabetes, which was less than half of that of severely obese mothers with insulin-treated pregestational diabetes. 21 Likewise, a retrospective cohort study 17 . 19 In addition, the offspring of severely obese mothers with type 2 diabetes had a more than 2-fold risk for specific developmental disorders compared with the offspring of normal-weight mothers without diabetes, whereas the corresponding effect size for obese mothers with insulin-treated pregestational diabetes was almost 3 times.
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One reason that insulin-treated pregestational diabetes had a higher effect size than type 2 diabetes (not treated with insulin) on the risk that offspring will have an ICD-10 F code diagnosis might be that mothers with insulin-treated pregestational diabetes have poorer glucose control.
Also, insulin plays a role in energy metabolism and other aspects of central nervous system function, 27 and insulin abnormalities may exacerbate cognitive impairment. 28 In fact, increased peripheral insulin results in insulin resistance, which itself has substantial outcomes on the brain 29 and has been associated with depression. [30] [31] [32] Furthermore, persons with, for example, ADHD and mood disorders have been reported to have an increased risk of developing obesity. Whether this is genetically or solely environmentally underpinned is not clear. 33, 34 However, common genetic risk factors for psychiatric disorders and obesity are known and can thus provide a possible partial explanation for the association of maternal obesity with the increased risk of psychiatric disorders in the offspring of mothers with diabetes. 35, 36 In children with type 1 diabetes, hypoglycemia events are associated with a higher risk of developing ADHD. 37 Finally, a sensitivity analysis was performed to estimate the risk for psychotropic medication purchase given maternal prepregnancy obesity and diabetes. Our findings supported the associations observed from the ICD-10 F code diagnosis-based analyses.

Limitations
This study has limitations. The analyses were adjusted for possible confounders with different frequencies in the group with type 2 diabetes compared with the group without diabetes (eTable 1 in the Supplement). [38] [39] [40] In an attempt to adjust for socioeconomic position, smoking and marital status were adjusted for because they are associated with more sophisticated measures of socioeconomic position 41 ; however, the availability of better indicators of socioeconomic position would have been desirable. Furthermore, reliable information on preeclampsia, blood glucose level, and metabolic control was not available. The purchase of glucose-lowering drugs other than insulin, such as ATC group A10B drugs (mainly metformin), during pregnancy was not adjusted for because few mothers purchased such drugs. Also, maternal BMI was obtained at only a single time point; thus, the association with gestational weight gain could not be examined. As discussed already, there is also potential residual confounding from genetic susceptibility, such as maternal and paternal outpatient psychiatric conditions, that were unavailable for this study. We could only exclude marked confounding from maternal inpatient psychiatric disorders and maternal purchase of ATC group N05 or N06 drugs (yes or no) during pregnancy, as seen for 1.8% and 5.8% of the mothers, respectively (eTable 1 in the Supplement). Analysis of exposure-discordant siblings were not possible because of an exposure concordance rate of more than 97% for diabetes (eTable 2 in the Supplement). Still, adjustment for the corresponding psychiatric diagnosis or psychotropic medication purchase outcome in the older sibling did not reduce the risk estimate of the association between diabetes exposure and offspring psychiatric disorder (eTable 4 in the Supplement).
Additional limitations include that, although the oldest birth year cohort could be followed up for 11 years (until 2014), those born at later birth years were followed up for shorter time, reducing the chance of debut of later-onset disorders ( Table 1 ). Between 27.0% and 39.8% of cases were detected for mood disorders, anxieties, eating disorders, intellectual disabilities, and specific developmental disorders, whereas 55.5% to 76.2% of cases were detected for sleeping disorders, ASD, ADHD and conduct disorders, and other behavioral and emotional disorders (ICD-10 code F98) ( Table 1 ). The risk for offspring psychiatric disorders or medication did not follow the pattern of proportion picked up. Moreover, there was no clear difference in age at diagnosis between those exposed to maternal obesity or diabetes and those not exposed (eTable 5 in the Supplement).
Furthermore, because we prioritized sensitivity over specificity in the detection of type 2 diabetes among the mothers, a diagnosis with ICD-10 code E14, or a purchase of an ATC group A10B drug, before pregnancy was enough to be classified as having type 2 diabetes. Thus, some mothers with true unspecified diabetes or prediabetes were probably included in the type 2 diabetes group.
However, 90% had a type 2 diabetes diagnosis according to ICD-10 codes O24.1 and E11. In addition, we did not adjust for multiple testing.
